Clinical trial
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
NCT00242346 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00242346 |
|---|---|
| Title | High Doses of Candesartan Cilexetil on the Reduction of Proteinuria |
| Official title | A Double-Blind, Randomised, Dose Ranging, Multi-Centre, Phase IIIb Study to Evaluate the Efficacy and Safety of High Doses of Candesartan Cilexetil (Atacand®) on the Reduction of Proteinuria in the Treatment of Subjects With Hypertension and Moderate to Severe Proteinuria |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Proteinuria |
| Intervention type | Drug |
| Interventions | candesartan cilexetil |
| Enrollment | 270 |
| Start date | Apr 1, 2003 |
| Completion | Dec 1, 2006 |
| First posted | Oct 20, 2005 |
| Last update posted | Dec 19, 2007 |
| Countries | Canada |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: